GleamWall
中文EN

ABVC ABVC BIOPHARMA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1173313 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY234.3%
TTM net income YoY62.5%
TTM EPS YoY76.7%
Revenue 3-yr CAGR12.7%
Net income 3-yr CAGR—

Margins

Gross margin99.9%
Operating margin-850.7%
Net margin-773.6%
FCF margin—
EBITDA margin-840.1%

Returns

ROE-283.6%
ROA-51.4%
ROIC (approx.)-570.9%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets90.4%
Debt / equity0.00x
Current ratio0.33x
Interest coverage-5.25x

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$296,000$509,589
Cost of revenue—$763
Gross profit—$508,826
R&D expense$121,085$179,272
SG&A expense$2.89M$2.26M
Operating income-$7.15M-$4.71M
Interest expense$415,890$825,899
Pretax income-$8.35M-$5.37M
Income tax$24,154-$110,539
Net income-$7.91M-$4.90M
EBITDA-$7.13M-$4.67M
EPS (basic)-0.39-0.42
EPS (diluted)-0.39-0.42
Weighted avg. shares (diluted)20.11M11.67M
Balance sheet
Cash & equivalents$681,480$863,815
Short-term investments$64,354$64,736
Current assets$3.26M$2.18M
PP&E, net$12.84M$511,088
Total assets$21.82M$7.54M
Current liabilities$6.92M$6.56M
Short-term debt$755,512$840,252
Total liabilities$8.52M$6.82M
Shareholders' equity$11.11M$1.23M
Shares outstanding25.05M13.87M
Cash flow statement
Operating cash flow-$2.99M-$1.81M
Investing cash flow-$1.21M—
Financing cash flow$4.64M$1.98M
Depreciation & amortization$25,330$32,025
Stock-based compensation$4.14M$2.77M

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.